NovelStem International (NSTM) stock price is $0.01, unchanged on the day, as of Nov 12, 2026. It has a market cap of $493.32K, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap493,324.54
P/E-1.62
FCF (Yr)-167,633.00
ROA (Yr)2,699.09
EV to EBIT-2.88
Net Income (Yr)2.39 Mn
Enterprise Value346,279.54
Add ratio to table…
About
NovelStem International Corp. is a holding company focused on biotechnology and intellectual property rights. The company's principal asset consists of rights to profits from a license held by Yissum Research Development Company, Hebrew University's technology transfer company, which it previously held through its ownership interest in NewStem Ltd. NovelStem derives value from its equity investments and associated technology licenses rather than from direct product sales or…
NovelStem International Corp. is a holding company focused on biotechnology and intellectual property rights. The company's principal asset consists of rights to profits from a license held by Yissum Research Development Company, Hebrew University's technology transfer company, which it previously held through its ownership interest in NewStem Ltd. NovelStem derives value from its equity investments and associated technology licenses rather than from direct product sales or services.
NovelStem generates revenue primarily through potential future licensing income from stem cell-based technology developed by Hebrew University under an exclusive license previously held by NewStem. The company retains a financial interest of up to $3,750,000 in any future licensing of this technology following the liquidation of NewStem in October 2025. Historically, NovelStem also received minimal distributions from its 50% equity interest in NetCo, a joint venture that owns the Net Force publishing franchise, before selling that interest in May 2025 to settle litigation funding liabilities.
The company operates through the following segments:
Biotechnology Holdings: This segment encompasses NovelStem's equity interest in NewStem Ltd and the associated stem cell technology license from Yissum. The technology focuses on haploid human pluripotent stem cells for genome-wide screenings, oncology drug discovery, and diagnostics for chemotherapy resistance. NovelStem provided $4 million in seed funding to NewStem between 2018 and 2020 and held a 30.51% equity interest at the time of NewStem's liquidation.
NetCo Joint Venture: This segment involved NovelStem's 50% ownership in NetCo, which owns the Net Force entertainment property covering film, television, and video game rights. NetCo licensed publishing rights to Putnam Berkley and later HarperCollins for Net Force books and novellas. NovelStem received distributions from its share of NetCo proceeds until selling its interest in May 2025 for $1,300,000 to settle related debt obligations.
NovelStem operates in the competitive biotechnology and intellectual property licensing sectors, where success depends on technological innovation, regulatory approval, and market adoption. The company faces competition from other firms developing stem cell-based therapies and diagnostic platforms, particularly those targeting cancer research and personalized medicine. Its competitive position relies on the exclusive nature of the licensed technology from Yissum and the potential for future monetization through downstream licensees, although no guarantee exists that others will not develop superior alternatives.
NovelStem's customer base consists of potential future licensees of the stem cell technology platform, including pharmaceutical companies, diagnostic firms, and research institutions interested in oncology drug development and chemotherapy resistance testing. Historically, through NetCo, the company served book publishers such as Putnam Berkley and HarperCollins, as well as audiences for Net Force film, television, and video game adaptations. Following the liquidation of NewStem and sale of NetCo, NovelStem's revenue prospects are tied to entities that may obtain licensing rights from Yissum for the underlying stem cell technology.
Sectors:Healthcare·Communication ServicesSector rationaleThe company's primary business and remaining assets are focused on biotechnology holdings, specifically licensing rights for stem cell-based technology used in oncology drug discovery and diagnostics. A secondary sector is included because the company previously operated a substantial business line through NetCo, which owned the Net Force publishing franchise and licensed rights for books, film, and television.Industries:BiotechnologyBiotechnologyPrimaryNovelStem's primary business focus is its biotechnology holdings, specifically rights to stem cell-based technology for genome-wide screenings and oncology drug discovery. The company's value and future revenue prospects are tied to the licensing of these biological therapies and diagnostic platforms.PublishingPublishingSecondaryThe company previously held a 50% equity interest in NetCo, which owned the Net Force publishing franchise and licensed book and novella publishing rights to HarperCollins and Putnam Berkley.Film and TelevisionFilm and TelevisionSecondaryThrough its interest in NetCo, the company held rights to the Net Force entertainment property, which specifically covered film and television rights.Classified using BQ-MICSCIK: 0000912544
Statement Business Segments Breakdown of Revenue (2012)